This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cowen, M. E. Articles by Kattan, M. W. Search for Related Content PubMed PubMed Citation Articles by Cowen, M. E. Articles by Kattan, M. W. Social Bookmarking                   What's this?

The Danger of Applying Group-level Utilities in Decision Analyses of the Treatment of Localized Prostate Cancer in Individual Patients

Brian J. Miles, MD

Daniel F. Cahill, MD

R. Brian Giesler, PhD

J. Robert Beck, MD

Michael W. Kattan, PhD

The optimal management strategy for men who have localized prostate cancer remains controversial. This study examines the extent to which suggested treatment based on the perspective of a group or society agrees with that derived from individual patients' preferences. A previously published decision analysis for localized prostate cancer was used to suggest the treatment that maximized quality-adjusted life expectancy. Two treatment recommendations were obtained for each patient: the first (group-level) was derived using the mean utilities of the cohort; the second (individual-level) used his own set of utilities. Group-level utilities misrepresented 25-48% of individuals' pref erences depending on the grade of tumor modeled. The best kappa measure achieved between group and individual preferences was 0.11. The average quality-adjusted life years lost due to misrepresentation of preference was as high as 1.7 quality-adjusted life years. Use of aggregated utilities in a group-level decision analysis can ignore the substantial variability at the individual level. Caution is needed when applying a group- level recommendation to the treatment of localized prostate cancer in an individual patient. Key words: decision analysis; utility assessment; prostate cancer; patient pref erences. (Med Decis Making 1998;18:376-380)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. E. Bremner, C. A. K. Y. Chong, G. Tomlinson, S. M. H. Alibhai, and M. D. Krahn A Review and Meta-Analysis of Prostate Cancer Utilities Med Decis Making, May 1, 2007; 27(3): 288 - 298. [Abstract] [PDF]

				A. Basu and D. Meltzer Value of Information on Preference Heterogeneity and Individualized Care Med Decis Making, March 1, 2007; 27(2): 112 - 127. [Abstract] [PDF]

				F Keller, G Allert, H Baitsch, G Sponholz, and Ethics in Medicine Working Group at the University Discourse ethics in practical medicine Med. Humanit., December 1, 2006; 32(2): 99 - 103. [Abstract] [Full Text] [PDF]

				J. H. Goldberg Being there is important, but getting there matters too: the role of path in the valuation process. Med Decis Making, July 1, 2006; 26(4): 323 - 337. [Abstract] [PDF]

				A. J. Stephenson, P. T. Scardino, J. A. Eastham, F. J. Bianco Jr, Z. A. Dotan, C. J. DiBlasio, A. Reuther, E. A. Klein, and M. W. Kattan Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy J. Clin. Oncol., October 1, 2005; 23(28): 7005 - 7012. [Abstract] [Full Text] [PDF]

				M. Man-Son-Hing, B. F. Gage, A. A. Montgomery, A. Howitt, R. Thomson, P. J. Devereaux, J. Protheroe, T. Fahey, D. Armstrong, and A. Laupacis Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making Med Decis Making, September 1, 2005; 25(5): 548 - 559. [Abstract] [PDF]

				E. B. Elkin, M. E. Cowen, D. Cahill, M. Steffel, and M. W. Kattan Preference Assessment Method Affects Decision-Analytic Recommendations: A Prostate Cancer Treatment Example Med Decis Making, October 1, 2004; 24(5): 504 - 510. [Abstract] [PDF]

				M. McNaughton-Collins, E. Walker-Corkery, and M. J. Barry Health-Related Quality of Life, Satisfaction, and Economic Outcome Measures in Studies of Prostate Cancer Screening and Treatment, 1990-2000 J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 78 - 101. [Abstract] [Full Text] [PDF]

				M. W. Kattan, S. F. Shariat, B. Andrews, K. Zhu, E. Canto, K. Matsumoto, M. Muramoto, P. T. Scardino, M. Ohori, T. M. Wheeler, et al. The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1 Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate Cancer J. Clin. Oncol., October 1, 2003; 21(19): 3573 - 3579. [Abstract] [Full Text] [PDF]

				S. M.H. Alibhai, G. Naglie, R. Nam, J. Trachtenberg, and M. D. Krahn Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer? J. Clin. Oncol., September 1, 2003; 21(17): 3318 - 3327. [Abstract] [Full Text] [PDF]

				A Bowling and S Ebrahim Measuring patients' preferences for treatment and perceptions of risk Qual. Saf. Health Care, September 1, 2001; 10(90001): i2 - 8. [Full Text] [PDF]

				M. Man-Son-Hing, A. Laupacis, A. M. O'Connor, D. Coyle, R. Berquist, and F. McAlister Patient Preference-based Treatment Thresholds and Recommendations: A Comparison of Decision-analytic Modeling with the Probability-tradeoff Technique Med Decis Making, October 1, 2000; 20(4): 394 - 402. [Abstract] [PDF]

				P. J. Nietert, M. R. Abboud, M. D. Silverstein, and S. M. Jackson Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis Blood, May 15, 2000; 95(10): 3057 - 3064. [Abstract] [Full Text] [PDF]